FDA To Scrutinize MDS Pharma Bioequivalence Study Methods
This article was originally published in The Pink Sheet Daily
CRO’s approach to investigating sources of contamination in bioequivalence studies is “inadequate,” the agency says in an “untitled” letter. MDS says it is “actively working to address the agency’s concerns.”
You may also be interested in...
A recent FDA inspection of MDS Pharma Services' Montreal bioanalytical facility has triggered an agency review of all bioequivalence studies conducted at the facility over the last five years. The contract research organization is reviewing its quality assurance practices.
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.